Diagnosis and specific prevention of hepatitis b in a specialized setting

Zh G Eremeeva; I K Minullin; O V Platonova; E V Bogdanova; V Kh Fazylov

doi:10.17750/KMJ2015-923

Kazan medical journal ›› 2015, Vol. 96 ›› Issue (6) : 923 -929. DOI: 10.17750/KMJ2015-923

Theoretical and clinical medicine

research-article

Diagnosis and specific prevention of hepatitis b in a specialized setting

Author information +

History +

PDF

Abstract

Aim. To evaluate the diagnostic approaches to viral hepatitis B and immune response on hepatitis B vaccination among clinical dispensary of dermatology and sexually transmitted diseases medical staff.

Methods. The study included 92 serum samples of healthcare facility staff who underwent hepatitis B vaccination more than 7 years before. To assess the post-vaccination immunity, levels of antibodies to surface antigen of hepatitis B (anti-HBS) were determined by ELISA. Published data on the duration of post-vaccination immunity and annual reporting forms of clinical dispensary of dermatology and sexually transmitted diseases of Kazan in 2013 were analyzed.

Results. Patients with human immunodeficiency virus, viral hepatitis B and C are often seeking for medical aid, retaining the risk for medical staff and other patients to be infected. Diagnosis of hepatitis B virus in medical settings is based on the detection of hepatitis B surface antigen (HBSAg), while revealing hepatitis B core antigen (HBCAg), anti-HBC (summary levels), extra-Dane particle antigen (HBEAg) and other markers of viral hepatitis B would allow to diagnose a latent form of hepatitis B. In 56.5% (n=92) of cases, anti-HBs levels were below the protective titer, suggesting higher risk for infection and requiring an additional revaccination. In the remaining 43.5% of cases, protective antibodies titers were revealed, confirming the effectiveness of specific prevention measures.

Conclusion. Despite the mass vaccination for hepatitis B, owing to post-vaccination immunity weakening over time, revaccination of medical staff remains important.

Keywords

viral hepatitis B / diagnosis / vaccination / immunity

Cite this article

Download citation ▾

Zh G Eremeeva, I K Minullin, O V Platonova, E V Bogdanova, V Kh Fazylov. Diagnosis and specific prevention of hepatitis b in a specialized setting. Kazan medical journal, 2015, 96(6): 923-929 DOI:10.17750/KMJ2015-923

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Абдукадырова М.А. Прогностические маркёры хронизации вирусного гепатита С. Иммунология. 2002; 23 (1): 47-50.

[2]	Бондаренко А.Л., Барамзина С.В. Неблагоприятные прогностические иммунологические и иммуногенетические факторы формирования цирроза печени у больных хроническим гепатитом В. Рос. ж. гастроэнтерол., гепатол. и колопроктол. 2004; 14 (4): 54-59.

[3]	Ивашкин В.Т., Герман Е.Н., Маевская М.В. Скрытая инфекция вирусом гепатита В. Рос. ж. гастроэнтерол., гепатол. и колопроктол. 2008; 18 (2): 4-11.

[4]	Мамаев С.Н., Шульпекова Ю.О., Левина А.А. Содержание провоспалительных цитокинов и факторов роста в сыворотке крови больных хроническими вирусными гепатитами и циррозом печени. Рос. ж. гастроэнтерол., гепатол. и колопроктол. 2000; 10 (5): 30-34.

[5]	МУ 3.1.2792-10 Профилактика инфекционных болезней. Эпидемиологический надзор за гепатитом B. Метод. указания. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2010; 37 с.

[6]	О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2013 году. Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2014; 191 с.

[7]	О состоянии санитарно-эпидемиологического благополучия населения в Республике Татарстан в 2013 году. Государственный доклад. Под общ. ред. М.А. Патяшиной - руководителя Управления Роспотребнадзора по Республике Татарстан (Татарстан). Казань. 2014; 212 с.

[8]

Bialek S.R., Bower W.A., Novak R. et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr. Infect. Dis. J. 2008; 27 (10): 881-885. http://dx.doi.org/10.1097/INF.0b013e31817702ba

[9]	Donato F., Gelatti U., Limina R.M., Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006; 25: 375 670. http://dx.doi.org/10.1038/sj.onc.1209557

[10]	Freeman A.J., Marinos G., French R.A. et al. Immunopathogenesis of hepatitis C virus infection. Immunol. Cell Biol. 2001; 79 (6): 515-536. http://dx.doi.org/10.1046/j.1440-1711.2001.01036.x